Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

HIV Infection

Free Subscription Articles published in HIV Med Retrieve available abstracts of 154 articles: HTML format

Single Articles

April 2025
1. 
   Correction to "Perception of medical care among women living with HIV aged 40 years or older-a European-wide survey".
   HIV Med. 2025 Apr 14. doi: 10.1111/hiv.70032.
   PubMed    
   
   
   
2. ADMASSU Z, Logie CH, Vahedi L, Underhill A, et al
   Longitudinal associations between social determinants of health and well-being among women living with HIV in Canada: A latent class analysis.
   HIV Med. 2025 Apr 14. doi: 10.1111/hiv.70031.
   PubMed     Abstract available
   
   
   
3. BARDA B, Barilaro G, Bellini P, Turicchi G, et al
   Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.
   HIV Med. 2025 Apr 9. doi: 10.1111/hiv.70025.
   PubMed     Abstract available
   
   
   
4. ZUBAIR A, Ahmad H, Arif MM, Ali M, et al
   mRNA vaccines against HIV: Hopes and challenges.
   HIV Med. 2025 Apr 7. doi: 10.1111/hiv.70024.
   PubMed     Abstract available
   
   
   
5. ZHAO J, Gao M, Zhao D, Tian W, et al
   Prevalence of late HIV diagnosis and its impact on mortality: A comprehensive systematic review and meta-analysis.
   HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70023.
   PubMed     Abstract available
   
   
   
6. CHACHU KH, Maboe KA
   Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.
   HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70022.
   PubMed     Abstract available
   
   
   March 2025
7. BARTOVSKA Z, Massmann R, Jilich D, Groh T, et al
   Late diagnosis of HIV among Ukrainian refugees in the Czech Republic: A retrospective, observational study.
   HIV Med. 2025 Mar 29. doi: 10.1111/hiv.70021.
   PubMed     Abstract available
   
   
   
8. AKSAK-WAS B, Skonieczna-Zydecka K, Parczewski M, Hrynkiewicz R, et al
   Rethinking HIV treatment: How non-integrase strand regimens may hold the key to better immune health.
   HIV Med. 2025 Mar 28. doi: 10.1111/hiv.70020.
   PubMed     Abstract available
   
   
   
9. MOSHI LS, Okuma J, Luoga E, Kalinjuma AV, et al
   Trends of severe HIV disease and mortality among children in rural Tanzania.
   HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70015.
   PubMed     Abstract available
   
   
   
10. SAUMOY M, Fernandez A, Tiraboschi J, Penafiel J, et al
    Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70017.
    PubMed     Abstract available
    
    
    
11. VASELLI NM, Salaveria K, Winearls J, Garnham K, et al
    Pneumocystis jirovecii pneumonia-Immune reconstitution inflammatory syndrome: A review of published cases.
    HIV Med. 2025 Mar 24. doi: 10.1111/hiv.70016.
    PubMed     Abstract available
    
    
    
12. MARTORELL C, Ramgopal M, Hagins D, Osiyemi O, et al
    Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
    HIV Med. 2025 Mar 21. doi: 10.1111/hiv.70018.
    PubMed     Abstract available
    
    
    
13. PINCUS KJ, Faridi N, Ryscavage PA, Seung H, et al
    Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use.
    HIV Med. 2025 Mar 20. doi: 10.1111/hiv.70019.
    PubMed     Abstract available
    
    
    
14. HERNANDEZ-TRUJILLO PN, Lopez-Baron CA, Arevalo-Pinzon G, Trujillo-Guiza ML, et al
    Taxonomic and functional profile of the anorectal microbiota in HIV-positive and HIV-negative men who have sex with men, using a metagenomic approach.
    HIV Med. 2025 Mar 18. doi: 10.1111/hiv.70014.
    PubMed     Abstract available
    
    
    
15. CHAWLA S, Kaida A, Brouillette MJ, Kleiner B, et al
    Impact of mental health service use on the HIV care cascade among women.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.70008.
    PubMed     Abstract available
    
    
    
16. SURIYARACHCHI DDC, Katuwavila NP
    Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.13770.
    PubMed     Abstract available
    
    
    
17. HE X, Zheng W, Wang X, Jiang Y, et al
    Trend of HIV/AIDS disease burden in China from 1990 to 2021: An age-period-cohort model analysis.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.70009.
    PubMed     Abstract available
    
    
    
18. 
    DOAK 2025 / 12th German-Austrian AIDS Congress, 20-22 March 2025, Hofburg Vienna.
    HIV Med. 2025;26 Suppl 1:3-82.
    PubMed    
    
    
    February 2025
19. GIFFORD AJ, Jaspal R, Jones BA, McDermott DT, et al
    Predicting PrEP acceptability and self-efficacy among men who have sex with men in the UK: The roles of identity resilience, science mistrust, and stigma.
    HIV Med. 2025 Feb 27. doi: 10.1111/hiv.13768.
    PubMed     Abstract available
    
    
    
20. HENDERSON M, Lyons D, Beddows S, Cowen M, et al
    High-risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.70001.
    PubMed     Abstract available
    
    
    
21. BEGUELIN C, Surial B, Hofmann E, Begre L, et al
    Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.13766.
    PubMed     Abstract available
    
    
    
22. BLANCH J, Martinez E, Mena A, Duenas C, et al
    Impact of training healthcare professionals in the detection and management of neuropsychiatric comorbidities in people with HIV: The CONECTAR project in Spain.
    HIV Med. 2025 Feb 24. doi: 10.1111/hiv.70002.
    PubMed     Abstract available
    
    
    
23. ELKHEIR N, Dominic C, Price A, Carter J, et al
    HIV in Latin American migrants in the UK: A neglected population in the 95-95-95 targets.
    HIV Med. 2025 Feb 24. doi: 10.1111/hiv.70007.
    PubMed     Abstract available
    
    
    
24. YU S, MacGibbon J, Bavinton B, Smith AKJ, et al
    Associations between country of birth, migration status and engagement in HIV care among gay and bisexual men living with HIV in Australia, 2019-2022.
    HIV Med. 2025 Feb 19. doi: 10.1111/hiv.13769.
    PubMed     Abstract available
    
    
    
25. AKASHANAND, Khatib MN, Serhan HA, Jena D, et al
    Spatial and temporal trends in HIV/AIDS burden among South Asian countries from 1990 to 2021: A systematic examination of the Global Burden of Disease study 2021.
    HIV Med. 2025 Feb 19. doi: 10.1111/hiv.70003.
    PubMed     Abstract available
    
    
    
26. MEDINA N, Alastruey-Izquierdo A, Bonilla O, Mercado D, et al
    Patients re-engaging with HIV care in Guatemala: Prioritizing CD4 counting and screening for histoplasmosis and tuberculosis.
    HIV Med. 2025 Feb 17. doi: 10.1111/hiv.70000.
    PubMed     Abstract available
    
    
    
27. SADIQ E, Woodiwiss A, Tade G, Nel J, et al
    The role of atherosclerosis in HIV-associated vasculopathy in young South African stroke patients.
    HIV Med. 2025 Feb 13. doi: 10.1111/hiv.13764.
    PubMed     Abstract available
    
    
    
28. NAZARENKO N, Chen YY, Borkowski P, Biavati L, et al
    Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
    HIV Med. 2025 Feb 13. doi: 10.1111/hiv.13760.
    PubMed     Abstract available
    
    
    
29. KUMAR S, Mehta R, Sah R, Verma A, et al
    Commentary on 'Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study'.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13767.
    PubMed    
    
    
    
30. YANG Q, Zhou J, Lan G, Qin Q, et al
    Factors influencing the quality of life and social skills of children living with HIV: A case-control study.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13758.
    PubMed     Abstract available
    
    
    
31. SALVO PF, Ciccullo A, Visconti E, Lombardi F, et al
    Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13765.
    PubMed     Abstract available
    
    
    January 2025
32. PINAR SS, Manak M, Saravanan S, Imami N, et al
    Point-of-care nucleic acid testing - a step forward in controlling the HIV epidemic: A review.
    HIV Med. 2025 Jan 25. doi: 10.1111/hiv.13757.
    PubMed     Abstract available
    
    
    
33. ODONGPINY EAL, Nicol M, Katana E, Owori J, et al
    A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda.
    HIV Med. 2025 Jan 24. doi: 10.1111/hiv.13761.
    PubMed     Abstract available
    
    
    
34. IZQUIERDO R, Suarez-Garcia I, Marco-Sanchez C, Perez-Latorre L, et al
    Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
    HIV Med. 2025 Jan 21. doi: 10.1111/hiv.13762.
    PubMed     Abstract available
    
    
    
35. MKHIZE N, Garrido J, Cole-Haley S, Diallo DD, et al
    Breaking down global barriers: A multinational and multi-community approach to combat stigma and enhance mental wellbeing in people with HIV.
    HIV Med. 2025 Jan 16. doi: 10.1111/hiv.13763.
    PubMed     Abstract available
    
    
    
36. MCGARRITY MW, MacPherson P, Li A, Naccarato M, et al
    Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery.
    HIV Med. 2025 Jan 15. doi: 10.1111/hiv.13759.
    PubMed     Abstract available
    
    
    
37. WALKER SH, Grierson J, Sullivan A, Alagaratnam J, et al
    The effects of the COVID-19 pandemic on people living with HIV.
    HIV Med. 2025 Jan 6. doi: 10.1111/hiv.13754.
    PubMed     Abstract available
    
    
    
38. HU T, Yang S, Yu J, Yang Z, et al
    Transitions in treatment: A systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders.
    HIV Med. 2025 Jan 2. doi: 10.1111/hiv.13756.
    PubMed     Abstract available
    
    
    December 2024
39. VARMA A, Singh MP, Sah S, Verma A, et al
    Commentary on 'DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy'.
    HIV Med. 2024 Dec 26. doi: 10.1111/hiv.13755.
    PubMed    
    
    
    
40. SANDULESCU O, Moseholm E
    Editorial comment on: "It's like it's the old boys Club: The age-related experiences of diverse older women living with HIV: A scoping review and consultative exercise".
    HIV Med. 2024 Dec 22. doi: 10.1111/hiv.13750.
    PubMed    
    
    
    
41. OKHAI H, Winston A, Post F, Boffito M, et al
    Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study.
    HIV Med. 2024 Dec 19. doi: 10.1111/hiv.13753.
    PubMed     Abstract available
    
    
    
42. MIRON VD, Sabin CA, Sandulescu O, Lourida G, et al
    Perception of medical care among women living with HIV aged 40 years or older-A European-wide survey.
    HIV Med. 2024 Dec 15. doi: 10.1111/hiv.13749.
    PubMed     Abstract available
    
    
    
43. KOKORELIAS KM, Su E, Brown P, McKinlay S, et al
    "It's like it's the old boys club"-the age-related experiences of diverse older women living with HIV: A scoping review and consultative exercise.
    HIV Med. 2024 Dec 12. doi: 10.1111/hiv.13751.
    PubMed     Abstract available
    
    
    
44. BARRE T, Ramier C, Ory K, Sogni P, et al
    Transient CD4 cell recovery after hepatitis C virus cure in HIV/hepatitis C virus coinfected patients (ANRS CO13 HEPAVIH cohort).
    HIV Med. 2024 Dec 11. doi: 10.1111/hiv.13752.
    PubMed    
    
    
    
45. ALFORD K, Sidat S, Bristowe K, Cicconi P, et al
    Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.
    HIV Med. 2024 Dec 10. doi: 10.1111/hiv.13748.
    PubMed     Abstract available
    
    
    
46. FALCI DR, Pasqualotto AC, Vieceli T, Sued O, et al
    Performance of urine Xpert MTB/RIF ultra in a tuberculosis screening strategy in hospitalized patients with advanced HIV disease: Results from an implementation initiative in Brazil.
    HIV Med. 2024 Dec 10. doi: 10.1111/hiv.13746.
    PubMed     Abstract available
    
    
    
47. SZETELA B, Bozejko M, Szymczak A, Giniewicz K, et al
    Rapid HIV pre-exposure prophylaxis (PrEP) initiation is safe and feasible: Experience from Wroclaw All Saints cohort in Poland 2017-2021.
    HIV Med. 2024 Dec 5. doi: 10.1111/hiv.13747.
    PubMed     Abstract available
    
    
    
48. D'ARMINIO MONFORTE A, Tavelli A, Quiros-Roldan E, Fabbiani M, et al
    Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naive and ART-experienced people with HIV in real-world setting: Data from the Icona cohort.
    HIV Med. 2024 Dec 2. doi: 10.1111/hiv.13740.
    PubMed     Abstract available
    
    
    
49. NELSON M, Bracchi M, Hunter E, Ong E, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of non-tuberculous mycobacteria 2024.
    HIV Med. 2024;25 Suppl 4:3-25.
    PubMed    
    
    
    November 2024
50. OJUKWU E, Pashaei A, Maia JC, Omobhude OF, et al
    Impact of the COVID-19 pandemic on the HIV care continuum and associated factors in middle-income countries: A mixed-methods systematic review.
    HIV Med. 2024 Nov 28. doi: 10.1111/hiv.13739.
    PubMed     Abstract available
    
    
    
51. JONES HT, Barber TJ
    A qualitative study of perspectives, experiences and priority outcomes for people living with HIV and frailty: Editorial comment on: "We are fragile, but we are strong": Navigating Frailty and HIV in Aging Populations: Perspectives on Language, Stigma
    HIV Med. 2024 Nov 28. doi: 10.1111/hiv.13736.
    PubMed    
    
    
    
52. YU X, Kuo YF, Dike AA, Efejuku T, et al
    Trends and disparities in antiretroviral therapy prescription rates among US Medicare beneficiaries with HIV.
    HIV Med. 2024 Nov 25. doi: 10.1111/hiv.13745.
    PubMed     Abstract available
    
    
    
53. BARBOSU CM, Avirvarei C, Manciuc C, Dye T, et al
    Stigma-associated attitudes and practices among Romanian clinical providers.
    HIV Med. 2024 Nov 25. doi: 10.1111/hiv.13742.
    PubMed     Abstract available
    
    
    
54. BLANCO JR, Gonzalez-Baeza A, Martinez-Vicente A, Albendin-Iglesias H, et al
    Loneliness and social isolation in people with HIV aged >/=50 years. The No One Alone (NOA)-GeSIDA study conducted by the GeSIDA 12021 study group.
    HIV Med. 2024 Nov 22. doi: 10.1111/hiv.13743.
    PubMed     Abstract available
    
    
    
55. PENNER J, Ombajo LA, Nkuranga J, Otieno E, et al
    High prevalence of osteoporosis among virally suppressed older people (>/=60 years) living with HIV.
    HIV Med. 2024 Nov 21. doi: 10.1111/hiv.13741.
    PubMed     Abstract available
    
    
    
56. BAKEWELL N, Kanitkar T, Dissanayake O, Symonds M, et al
    Comparing short-term mortality between people with and without HIV admitted to the intensive care unit: A single-centre matched cohort study (2000-2019).
    HIV Med. 2024 Nov 20. doi: 10.1111/hiv.13737.
    PubMed     Abstract available
    
    
    
57. METCALFE R, Fraser R, Trayner KMA, Glancy M, et al
    Rising mortality among people who inject drugs living with HIV in Scotland, UK: A 20-year retrospective cohort study.
    HIV Med. 2024 Nov 18. doi: 10.1111/hiv.13733.
    PubMed     Abstract available
    
    
    
58. KENIYOPOULLOS R, Khawaja AA, Boffito M, Emerson M, et al
    In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors.
    HIV Med. 2024 Nov 15. doi: 10.1111/hiv.13738.
    PubMed     Abstract available
    
    
    
59. BLAKEY EG, Fairhead CEL, Rodger AJ, Burns FM, et al
    Clinical staff attitudes towards opt-out consent for blood-borne virus screening in emergency departments in England.
    HIV Med. 2024 Nov 13. doi: 10.1111/hiv.13735.
    PubMed     Abstract available
    
    
    
60. RODKJAER LO, Storgaard M, Schougaard LMV
    Implementation of patient-reported outcomes for people living with HIV: Insights from patients and healthcare providers in a Danish outpatient clinic.
    HIV Med. 2024 Nov 13. doi: 10.1111/hiv.13734.
    PubMed     Abstract available
    
    
    
61. SEMPERE A, Gonzalez-Rioja X, Martinez E
    AI in medicine: No longer the future, but the present.
    HIV Med. 2024 Nov 11. doi: 10.1111/hiv.13732.
    PubMed    
    
    
    
62. LAGUNO M, de Lazzari E, Berrocal L, Inciarte A, et al
    Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV.
    HIV Med. 2024 Nov 7. doi: 10.1111/hiv.13730.
    PubMed     Abstract available
    
    
    
63. ABGRALL S, Selinger-Leneman H, Lanoy E, Becker A, et al
    Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH).
    HIV Med. 2024 Nov 4. doi: 10.1111/hiv.13729.
    PubMed     Abstract available
    
    
    October 2024
64. STEPHAN C, Spinner CD, Rieke A, Christensen S, et al
    Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
    HIV Med. 2024 Oct 30. doi: 10.1111/hiv.13728.
    PubMed     Abstract available
    
    
    
65. WATERS L, Martinez E
    Cardiovascular prevention: Statins and beyond-A message from the editors of the special issue of HIV medicine.
    HIV Med. 2024 Oct 29. doi: 10.1111/hiv.13731.
    PubMed    
    
    
    
66. HICKS WL, Khalil S, Burke FW, Ho MQ, et al
    Comparison of risk factors and mortality in veterans with HIV and those without HIV suffering first major acute cardiovascular events.
    HIV Med. 2024 Oct 27. doi: 10.1111/hiv.13724.
    PubMed     Abstract available
    
    
    
67. IZQUIERDO R, Suarez-Garcia I, Gomez-Garcia T, Marco-Sanchez C, et al
    Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
    HIV Med. 2024 Oct 25. doi: 10.1111/hiv.13726.
    PubMed     Abstract available
    
    
    
68. FERNANDES G, Chappell E, Goetghebuer T, Kahlert CR, et al
    HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey.
    HIV Med. 2024 Oct 23. doi: 10.1111/hiv.13723.
    PubMed     Abstract available
    
    
    
69. FONSECA F, Avelino-Silva VI, Odoke W, van den Hombergh J, et al
    Are people with HIV at advanced disease stages being left behind? A global survey.
    HIV Med. 2024 Oct 18. doi: 10.1111/hiv.13725.
    PubMed     Abstract available
    
    
    
70. CLAIR-SULLIVAN NS, Vera JH, Maddocks M, Harding R, et al
    'We are fragile, but we are strong': A qualitative study of perspectives, experiences and priority outcomes for people living with HIV and frailty.
    HIV Med. 2024 Oct 13. doi: 10.1111/hiv.13722.
    PubMed     Abstract available
    
    
    
71. MA Y, Achiche S, Tu G, Vicente S, et al
    The first AI-based Chatbot to promote HIV self-management: A mixed methods usability study.
    HIV Med. 2024 Oct 10. doi: 10.1111/hiv.13720.
    PubMed     Abstract available
    
    
    
72. ERON JJ, Ramgopal M, Osiyemi O, Mckellar M, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.
    HIV Med. 2024 Oct 6. doi: 10.1111/hiv.13721.
    PubMed     Abstract available
    
    
    
73. TRAYNER KMA, Palmateer NE, McAuley A, Yeung A, et al
    Examining trends in the incidence of HIV infection among people with a history of drug use to inform an outbreak investigation and response: A retrospective cohort study.
    HIV Med. 2024 Oct 4. doi: 10.1111/hiv.13712.
    PubMed     Abstract available
    
    
    
74. PLATTEAU T, Herrijgers C, Barvaux V, Vanden Berghe W, et al
    Chemsex and its impact on gay and bisexual men who have sex with men: Findings from an online survey in Belgium.
    HIV Med. 2024 Oct 3. doi: 10.1111/hiv.13717.
    PubMed     Abstract available
    
    
    September 2024
75. GUTIERREZ F
    "Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study".
    HIV Med. 2024 Sep 27. doi: 10.1111/hiv.13719.
    PubMed    
    
    
    
76. NIMKAR S, Kinikar A, Mave V, Khol V, et al
    Long-term risk of mortality and loss to follow-up in children and adolescents on antiretroviral therapy in Asia.
    HIV Med. 2024 Sep 26. doi: 10.1111/hiv.13718.
    PubMed     Abstract available
    
    
    
77. MENDES-FERREIRA AAC, Veras NMC, Pinho REGG, Pascom AR, et al
    HIV drug resistance, viral suppression, and survival in children living with HIV in Brazil.
    HIV Med. 2024 Sep 25. doi: 10.1111/hiv.13714.
    PubMed     Abstract available
    
    
    
78. NAZARETH J, Adebayo A, Fahad M, Karim H, et al
    Cardiovascular medication adherence testing in patients living with HIV: A single-centre observational study.
    HIV Med. 2024 Sep 24. doi: 10.1111/hiv.13715.
    PubMed     Abstract available
    
    
    
79. MANYARA AM, Manyanga T, Burton A, Wilson H, et al
    Prevalence, factors and quality of life associated with frailty and pre-frailty in middle-aged and older adults living with HIV in Zimbabwe: A cross-sectional study.
    HIV Med. 2024 Sep 20. doi: 10.1111/hiv.13716.
    PubMed     Abstract available
    
    
    
80. FAROOQ HZ, Whitton L, Mwendera C, Divall P, et al
    Virtual care pathways for people living with HIV: A mixed-methods systematic review.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13701.
    PubMed     Abstract available
    
    
    
81. WOODS J, Sokhela S, Akpomiemie G, Bosch B, et al
    DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13711.
    PubMed     Abstract available
    
    
    
82. DAY S, Rae C, McOwan A, Wilkins R, et al
    Patient evaluation of Klick, a technology-enabled, nurse-delivered HIV outpatient pathway.
    HIV Med. 2024 Sep 15. doi: 10.1111/hiv.13710.
    PubMed     Abstract available
    
    
    
83. 
    Correction to "Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis".
    HIV Med. 2024 Sep 11. doi: 10.1111/hiv.13713.
    PubMed    
    
    
    
84. BARBER TJ, Clarke A, Fox A, Mackie NE, et al
    CROI 2024 BHIVA working group summary.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13705.
    PubMed     Abstract available
    
    
    
85. YANG X, Shi F, Zhang H, Giang WA, et al
    Long COVID among people with HIV: A systematic review and meta-analysis.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13708.
    PubMed     Abstract available
    
    
    
86. PINEIRO C, Policarpo S, Caldas C, Santos L, et al
    Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
    HIV Med. 2024 Sep 6. doi: 10.1111/hiv.13699.
    PubMed     Abstract available
    
    
    
87. PREVOTEAU DU CLARY F, Majerholc C, Zucman D, Livrozet JM, et al
    Evaluation of HIV antiretroviral treatment adherence in 2019 using anonymized data from the French national health insurance claims data base: The COCOVIH study.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13690.
    PubMed     Abstract available
    
    
    
88. MCCALL KL, Cabral DL, Coghlan JF, Concepcion AM, et al
    Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13709.
    PubMed     Abstract available
    
    
    
89. SHU Y, Zhang M, Li J, Deng X, et al
    Trajectories of CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio in patients with HIV and long-term virological suppression based on Yunnan HIV cohort.
    HIV Med. 2024 Sep 2. doi: 10.1111/hiv.13707.
    PubMed     Abstract available
    
    
    August 2024
90. KO S, Dominguez-Dominguez L, Ottaway Z, Campbell L, et al
    Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom.
    HIV Med. 2024 Aug 29. doi: 10.1111/hiv.13706.
    PubMed     Abstract available
    
    
    
91. URSENBACH A, Sireyjol A, Delpierre C, Duvivier C, et al
    Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study.
    HIV Med. 2024 Aug 28. doi: 10.1111/hiv.13698.
    PubMed     Abstract available
    
    
    
92. LI N, Thomas L, Allan A, John B, et al
    Optimizing statin prescriptions for people living with HIV: Evidence for improved communication and shared care between primary care and specialist HIV services.
    HIV Med. 2024 Aug 26. doi: 10.1111/hiv.13704.
    PubMed     Abstract available
    
    
    
93. HSU RK, Brunet L, Lackey PC, Pierone G Jr, et al
    Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study.
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13700.
    PubMed     Abstract available
    
    
    
94. GRINSPOON SK, Lu MT, Zanni MV, Diggs MR, et al
    What have we learned from the REPRIEVE trial and where do we go from here?
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13703.
    PubMed    
    
    
    
95. VASHISHT S, Thakur N, Kant S, Rai S, et al
    Assessment of targeted intervention programme under the National AIDS Control Program among men who have sex with men in India.
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13702.
    PubMed     Abstract available
    
    
    
96. SWIFT E, Upton G, Fitzpatrick C, Roberts J, et al
    Impact of omission of routine blood monitoring of stable patients living with HIV during the coronavirus pandemic.
    HIV Med. 2024 Aug 18. doi: 10.1111/hiv.13696.
    PubMed     Abstract available
    
    
    
97. CHAN CK, Huang SS, Wong KH, Leung CC, et al
    No increased risk of tuberculosis-related immune reconstitution inflammatory syndrome with integrase inhibitor-based antiretroviral therapy in people with HIV with profound immunosuppression.
    HIV Med. 2024 Aug 12. doi: 10.1111/hiv.13695.
    PubMed     Abstract available
    
    
    
98. WHITE TM, Fuster-RuizdeApodaca MJ, Iniesta C, Prats-Silvestre C, et al
    Network analysis to prioritize issues for intervention to improve the health-related quality of life of people with HIV in Spain.
    HIV Med. 2024 Aug 10. doi: 10.1111/hiv.13693.
    PubMed     Abstract available
    
    
    
99. BEKELE A, Ahmed I, Tefera F, Yimam JA, et al
    Incidence and predictors of attrition from HIV treatment among adults living with HIV in high-caseload facilities following implementation of universal test and treat strategy in Ethiopia: A prospective cohort study.
    HIV Med. 2024 Aug 6. doi: 10.1111/hiv.13691.
    PubMed     Abstract available
    
    
    
100. SAH S, Verma A, Zahiruddin QS, Rustagi S, et al
     Commentary on 'Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)'.
     HIV Med. 2024 Aug 1. doi: 10.1111/hiv.13689.
     PubMed    
     
     
     
101. KABLAWI D, Milic J, Thomas T, Fotsing Tadjo T, et al
     Metabolic dysfunction-associated steatohepatitis exhibits sex differences in people with HIV.
     HIV Med. 2024 Aug 1. doi: 10.1111/hiv.13697.
     PubMed     Abstract available
     
     
     July 2024
102. INESTROZA K, Hurtado V, Larson ME, Satish S, et al
     Characterizing heart failure and its subtypes in people living with HIV.
     HIV Med. 2024 Jul 30. doi: 10.1111/hiv.13694.
     PubMed     Abstract available
     
     
     
103. PIACENTINI D, Nicolini G, Bugana D, Piccolin G, et al
     Breastfeeding in women living with HIV in high-income countries: It's time to act.
     HIV Med. 2024 Jul 30. doi: 10.1111/hiv.13692.
     PubMed    
     
     
     
104. SCOFIELD D, Frisch M, Andersson M, Storgaard M, et al
     Psychosocial and sexual health among men with and without HIV who have sex with men: A cross-sectional nationwide study in Denmark.
     HIV Med. 2024 Jul 18. doi: 10.1111/hiv.13688.
     PubMed     Abstract available
     
     
     
105. RUIZ-BILBAO S, Videla S, Pascual E, Soler M, et al
     Functional and structural neuroretinal disorders in HIV Controllers. Prospective cohort study.
     HIV Med. 2024 Jul 9. doi: 10.1111/hiv.13685.
     PubMed     Abstract available
     
     
     
106. ZAJDMAN-FAITELSON D, Cardenas-Hernandez ML, Guzman-Bucio S, Camiro-Zuniga A, et al
     Clinicopathological concordance of mucocutaneous manifestations in people living with HIV: A cross-sectional study.
     HIV Med. 2024 Jul 8. doi: 10.1111/hiv.13686.
     PubMed     Abstract available
     
     
     
107. VERMA A, Pant M, Khatib MN, Singh MP, et al
     Commentary on 'Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities'.
     HIV Med. 2024 Jul 2. doi: 10.1111/hiv.13687.
     PubMed    
     
     
     June 2024
108. SIMOES D, Raben D, Moran AB, Imaz A, et al
     The HepHIV 2023 Madrid conference: A call to action for political leadership in reaching the sustainable development goals on earlier testing and linkage to care for HIV, viral hepatitis, and sexually transmitted infections.
     HIV Med. 2024 Jun 24. doi: 10.1111/hiv.13683.
     PubMed     Abstract available
     
     
     
109. BARQUET-MUNOZ SA, Lopez-Morales RA, Stier EA, Mejorada-Pulido E, et al
     Prevalence of anal high-risk human papillomavirus (HR-HPV) types in people living with HIV and a history of cancer.
     HIV Med. 2024 Jun 20. doi: 10.1111/hiv.13684.
     PubMed     Abstract available
     
     
     
110. BASOULIS D, Mastrogianni E, Eliadi I, Papadopoulou M, et al
     HCV-HIV co-infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece.
     HIV Med. 2024 Jun 20. doi: 10.1111/hiv.13681.
     PubMed     Abstract available
     
     
     
111. LAM JO, Hou CE, Alexeeff S, Levine T, et al
     Clinically recognized sleep disorders in people living with HIV.
     HIV Med. 2024 Jun 18. doi: 10.1111/hiv.13682.
     PubMed     Abstract available
     
     
     
112. RING K, Smuk M, Shongwe M, Okonta L, et al
     Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
     HIV Med. 2024 Jun 10. doi: 10.1111/hiv.13679.
     PubMed     Abstract available
     
     
     
113. HUTCHINSON J, Neesgard B, Kowalska J, Grabmeier-Pfistershammer K, et al
     Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men.
     HIV Med. 2024 Jun 5. doi: 10.1111/hiv.13662.
     PubMed     Abstract available
     
     
     
114. MALAGNINO V, Cozzi-Lepri A, Svicher V, Girardi E, et al
     Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy.
     HIV Med. 2024 Jun 4. doi: 10.1111/hiv.13680.
     PubMed     Abstract available
     
     
     
115. PASIN C, Nunez DG, Kusejko K, Hachfeld A, et al
     Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.
     HIV Med. 2024 Jun 3. doi: 10.1111/hiv.13677.
     PubMed     Abstract available
     
     
     May 2024
116. CHROMY D, Urban N, Bauer WM, Kreuter A, et al
     Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak.
     HIV Med. 2024 May 30. doi: 10.1111/hiv.13678.
     PubMed     Abstract available
     
     
     
117. INGILIZ P, Lutz T, Schewe K, Baumgarten A, et al
     Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemic.
     HIV Med. 2024 May 29. doi: 10.1111/hiv.13651.
     PubMed     Abstract available
     
     
     
118. SCHMIDT AJ, Weatherburn P, Wang H, Lutz T, et al
     Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021.
     HIV Med. 2024 May 27. doi: 10.1111/hiv.13657.
     PubMed     Abstract available
     
     
     
119. SZCZEPANSKI A, Klesiewicz K, Ankiersztejn-Bartczak M, Drozdz K, et al
     Voluntary counselling and testing points (VCTs) in Poland as a complementary and accessible alternative to public healthcare facilities: A comparative analysis of epidemiological data from the VCTs and the National Institute of Public Health NIH-Natio
     HIV Med. 2024 May 21. doi: 10.1111/hiv.13658.
     PubMed     Abstract available
     
     
     
120. YANG X, Zhang G, Kang W, Guo J, et al
     Related barriers to using HIV pre-exposure prophylaxis among MSM: A multicentre cross-sectional survey.
     HIV Med. 2024 May 21. doi: 10.1111/hiv.13663.
     PubMed     Abstract available
     
     
     
121. KATLAMA C, Bisshop F, Bogner J, Perez Elias MJ, et al
     Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
     HIV Med. 2024 May 17. doi: 10.1111/hiv.13643.
     PubMed     Abstract available
     
     
     
122. LOGIE CH, Sokolovic N, Casale A, Ndung'u M, et al
     Clinical HIV outcome trajectories associated with a history of child protective service out-of-home care: Longitudinal cohort findings with women living with HIV in Canada.
     HIV Med. 2024 May 17. doi: 10.1111/hiv.13660.
     PubMed     Abstract available
     
     
     
123. LUMBRERAS ARETA M, Migliorelli Falcone FE, Rudin C, Kahlert CR, et al
     Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study.
     HIV Med. 2024 May 16. doi: 10.1111/hiv.13652.
     PubMed     Abstract available
     
     
     
124. BUSCA-ARENZANA C, Ortega-Gonzalez D, Diaz-Almiron M, Montes ML, et al
     Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.
     HIV Med. 2024 May 15. doi: 10.1111/hiv.13659.
     PubMed     Abstract available
     
     
     
125. NAKAMURA H, Yamamoto K
     Mpox in people with HIV: A narrative review.
     HIV Med. 2024 May 15. doi: 10.1111/hiv.13661.
     PubMed     Abstract available
     
     
     
126. BROWN L, Sargent P, Islam M, Downie C, et al
     Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat.
     HIV Med. 2024 May 9. doi: 10.1111/hiv.13656.
     PubMed     Abstract available
     
     
     
127. FINLAYSON-TRICK E, Tam C, Wang L, Dawydiuk N, et al
     Access to care and impact on HIV treatment interruptions during the COVID-19 pandemic among people living with HIV in British Columbia.
     HIV Med. 2024 May 9. doi: 10.1111/hiv.13654.
     PubMed     Abstract available
     
     
     
128. MATACOTTA JJ, Tran D, Yoon S
     The prevalence of major depressive disorder in people with HIV: Results from the All of Us Research Program.
     HIV Med. 2024 May 7. doi: 10.1111/hiv.13653.
     PubMed     Abstract available
     
     
     
129. OOSTERHOF P, de Zoete BGJA, Vanhommerig JW, Langebeek N, et al
     De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study.
     HIV Med. 2024 May 7. doi: 10.1111/hiv.13655.
     PubMed     Abstract available
     
     
     
130. DOCKRELL DH, Breen R, Collini P, Lipman MCI, et al
     British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of pulmonary opportunistic infections 2024.
     HIV Med. 2024;25 Suppl 2:3-37.
     PubMed    
     
     
     
131. GREIG J, Bamford A, Chadwick D, Darley A, et al
     British HIV Association guidelines on the management of opportunistic infection in people living with HIV: Considerations in pregnancy 2024.
     HIV Med. 2024;25 Suppl 3:3-19.
     PubMed    
     
     
     April 2024
132. LLIBRE JM, Garcia F, Blanco JL, Pelaez EP, et al
     Prevalence of people living with multidrug-resistant HIV and limited treatment options in Spain.
     HIV Med. 2024 Apr 30. doi: 10.1111/hiv.13650.
     PubMed     Abstract available
     
     
     
133. DINESHA TR, Boobalan J, Kumar CV, Manikandan P, et al
     HIV-1 low-level viraemia predicts virological failure in first-line and second-line ART-experienced individuals in India: A retrospective longitudinal study.
     HIV Med. 2024 Apr 25. doi: 10.1111/hiv.13641.
     PubMed     Abstract available
     
     
     
134. BULLO M, Kierszenowicz T, Acosta MC, Rolon MJ, et al
     Telemedicine in HIV health care during the COVID-19 pandemic: An implementation research study in Buenos Aires, Argentina.
     HIV Med. 2024 Apr 24. doi: 10.1111/hiv.13646.
     PubMed     Abstract available
     
     
     
135. JOHN M, Williams L, Nolan G, Bonnett M, et al
     Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
     HIV Med. 2024 Apr 21. doi: 10.1111/hiv.13647.
     PubMed     Abstract available
     
     
     
136. DEMA E, Peters H, Gilleece Y, Thorne C, et al
     Residential and healthcare mobility during pregnancy among women living with HIV in the UK, 2009-2019.
     HIV Med. 2024 Apr 10. doi: 10.1111/hiv.13648.
     PubMed     Abstract available
     
     
     
137. OZHMEGOVA E, Lebedev A, Antonova A, Kuznetsova A, et al
     Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia.
     HIV Med. 2024 Apr 7. doi: 10.1111/hiv.13642.
     PubMed     Abstract available
     
     
     
138. CALZA L, Giglia M, Colangeli V, Bon I, et al
     Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
     HIV Med. 2024 Apr 3. doi: 10.1111/hiv.13644.
     PubMed     Abstract available
     
     
     
139. 
     BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
     HIV Med. 2024;25 Suppl 1:21-111.
     PubMed    
     
     
     
140. 
     BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
     HIV Med. 2024;25 Suppl 1:3-16.
     PubMed    
     
     
     
141. 
     BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
     HIV Med. 2024;25 Suppl 1:17-20.
     PubMed    
     
     
     March 2024
142. LIU Y, Cheng Z, Xian Y, Liu X, et al
     Cascade analysis of awareness, willingness, uptake and adherence with regard to PrEP among young men who have sex with men (YMSM) in China: A comparison between students and non-students.
     HIV Med. 2024 Mar 27. doi: 10.1111/hiv.13639.
     PubMed     Abstract available
     
     
     
143. OTTAWAY Z, Campbell L, Fox J, Burns F, et al
     HIV outcomes during the COVID-19 pandemic in people of Black ethnicities living with HIV in England.
     HIV Med. 2024 Mar 26. doi: 10.1111/hiv.13640.
     PubMed     Abstract available
     
     
     
144. SAWRY S, Ayalew K, Maimela G, Briggs-Hagen M, et al
     Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
     HIV Med. 2024 Mar 22. doi: 10.1111/hiv.13638.
     PubMed     Abstract available
     
     
     
145. ZOU S, Chen Z, Tan Y, Tan M, et al
     Microbiomes detected by cerebrospinal fluid metagenomic next-generation sequencing among patients with and without HIV with suspected central nervous system infection.
     HIV Med. 2024 Mar 21. doi: 10.1111/hiv.13634.
     PubMed     Abstract available
     
     
     
146. SOCIAS ME, Cui Z, Le Foll B, Lei J, et al
     Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial.
     HIV Med. 2024 Mar 20. doi: 10.1111/hiv.13636.
     PubMed     Abstract available
     
     
     
147. JACOBS TG, Okemo D, Ssebagereka A, Mwehonge K, et al
     Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
     HIV Med. 2024 Mar 18. doi: 10.1111/hiv.13635.
     PubMed     Abstract available
     
     
     
148. DOU Y, Lu R, Su L, Lan K, et al
     Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
     HIV Med. 2024 Mar 17. doi: 10.1111/hiv.13632.
     PubMed     Abstract available
     
     
     
149. VIOLETTE LR, Thomas KK, Dorward J, Quame-Amaglo J, et al
     Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa.
     HIV Med. 2024 Mar 15. doi: 10.1111/hiv.13633.
     PubMed     Abstract available
     
     
     
150. ZHAO J, Zhang L, Li L, Xie X, et al
     Growth of infants delivered by mothers with HIV in Guangxi, China: An 18-month longitudinal follow-up study, 2015-2021.
     HIV Med. 2024 Mar 13. doi: 10.1111/hiv.13624.
     PubMed     Abstract available
     
     
     
151. TAHA AM, Elrosasy A, Mahmoud AM, Saed SAA, et al
     The effect of HIV and mpox co-infection on clinical outcomes: Systematic review and meta-analysis.
     HIV Med. 2024 Mar 5. doi: 10.1111/hiv.13622.
     PubMed     Abstract available
     
     
     
152. PALICH R, Rodger AJ, Nicholls EJ, Wright T, et al
     Experiences with health care services and HIV testing after sexual assault in cisgender gay, bisexual and other men who have sex with men and transgender people.
     HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13629.
     PubMed     Abstract available
     
     
     
153. FURSA O, Bannister W, Neesgaard B, Podlekareva D, et al
     SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
     HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13620.
     PubMed     Abstract available
     
     
     
154. NOE S, Ivanova A, Johnsson-Oldenbuttel C, Schafer G, et al
     Immunological alterations with GLP-1 agonists in people living with HIV.
     HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13631.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.